Interaction of a fragment of the cannabinoid CB1 receptor C-terminus with arrestin-2  by Bakshi, Kunal et al.
FEBS Letters 581 (2007) 5009–5016Interaction of a fragment of the cannabinoid CB1 receptor
C-terminus with arrestin-2
Kunal Bakshia, Richard W. Mercierb, Spiro Pavlopoulosa,*
a Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road, U-3092, Storrs, CT 06269, USA
b Center for Drug Discovery, Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road,
U-3092, Storrs, CT 06269, USA
Received 25 May 2007; revised 13 September 2007; accepted 14 September 2007
Available online 24 September 2007
Edited by Christian GriesingerAbstract Desensitization of the cannabinoid CB1 receptor is
mediated by the interaction with arrestin. In this study, we report
the structural changes of a synthetic diphosphorylated peptide
corresponding to residues 419–439 of the CB1 C-terminus upon
binding to arrestin-2. This segment is pivotal to the desensitiza-
tion of CB1. Using high-resolution proton NMR, we observe two
helical segments in the bound peptide that are separated by the
presence a glycine residue. The binding we observe is with a di-
phoshorylated peptide, whereas a previous study reported binding
of a highly phosphorylated rhodopsin fragment to visual arrestin.
The arrestin bound conformations of the peptides are compared.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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An essential feature of G-protein coupled receptor (GPCR)
function is the regulation of signal transduction by arrestins
[1]. G-protein coupled receptors (GPCRs) are the largest
known family of membrane bound receptors, also referred to
as seven-transmembrane receptors (7TM) as they feature seven
membrane spanning helices ﬂanked by an extracellular N-ter-
minal region and an intracelluar C-terminal region [2–4].
GPCRs regulate a diverse array of important physiological
functions such as phototransduction, olfaction, neurotrans-
mission, vascular tone, cardiac output, digestion, and pain
and are widely recognized as the largest class of drug targets
for developing pharmaceuticals [5]. Upon activation GPCRs
cause heterotrimeric G proteins to mobilize and dissociate, ini-
tiating multiple signaling events [6], however, equally impor-
tant, is the cessation of these signaling events [7,8]. This is
accomplished by phosphorylation of the GPCR C-terminus
by G-protein coupled receptor kinases, concomitant with bind-
ing to cytosolic arrestins. This causes the uncoupling of the
GPCR-G-protein signaling complex and a decrease in the
intracellular transduction response, a process referred to as
desensitization [9–14]. In addition to desensitization, the bind-
ing of arrestins also promotes the internalization of GPCRs*Corresponding author. Fax: +1 860 486 6857.
E-mail address: s.pavlopoulos@uconn.edu (S. Pavlopoulos).
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.09.030[15,16]. Once internalized, GPCRs may undergo traﬃcking to-
wards degradation or recycling pathways. It has more recently
been shown that bound arrestin allows the internalized GPCR
to interface with a wider range of second messenger pathways
than previously thought [17,18]. There is biochemical evidence
to suggest that the nature of the phosphorylation of the GPCR
governs the interaction with arrestin and hence, the eventual
fate of the receptor [19–21].
Members of the arrestin family include arrestin-1 (or visual
arrestin) and arrestin-4 (or cone arrestin) that speciﬁcally mod-
ulate the action of rhodopsin, a photosensitive GPCR found in
the retina [22,23]. In contrast, arrestin-2 (b-arrestin-1) and
arrestin-3 (b-arrestin-2) modulate the action of non-retinal
GPCRs [1,11,24]. There has been signiﬁcant work to provide
structural information on arrestins [23,25,26], however, direct
measurement of the structures formed by arrestin-GPCR com-
plexes is lacking. Such direct biophysical measurements con-
cerning the nature of complexes between arrestins and
GPCRs are limited to arrestin-1 and rhodopsin [27–29].
In this study, we examine the conformational changes in a
segment of the human CB1 cannabinoid receptor upon bind-
ing to arrestin-2. CB1 is a G-protein coupled, membrane
bound receptor that is currently of great interest as a drug tar-
get [30]. It is hypothesized that residues 401–473 comprise the
C-terminus of CB1 that extends intracellularly from the cell
membrane [31]. The segment of the C-terminus between Gly-
418 and Asn-439 is crucial to arrestin mediated desensitization
as mutations in this region, particularly at Ser-426 and Ser-
430, result in decreased desensitization with no eﬀect on inter-
nalization [19,20]. In this study, we employ transferred nuclear
Overhauser (TrNOE) spectroscopy [32] to show a signiﬁcant
conformational change in a synthetic peptide corresponding
to CB1 amino acid residues 419–438 (CB1419–438), upon bind-
ing to arrestin-2.2. Materials and methods
2.1. Peptide synthesis
The diphosphorylated synthetic peptide CB1419–438 (Fig. 1) was ob-
tained from New England Peptides at >95% purity as shown by HPLC
and MALDI-TOF DE mass spectral analysis.
2.2. Expression of arrestin-2
cDNA encoding the human arrestin-2 ARRB1 variant 1 (Accession
No. NM_004041; splice variant containing an additional eight amino
acids as compared to variant two) was ampliﬁed from a human hypo-
thalamus cDNA library (Quick clone cDNA library, Clontech, Paloblished by Elsevier B.V. All rights reserved.
                            1          2        3        4          5       6          7        8        9        10      11       12      13      14      15      16       17     18      19      20 
CB1419-438 Thr Ala Gln Pro Leu Asp Asn Ser Met Gly Asp Ser Asp Cys Leu His Lys His Ala Asn
419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438
Rh330-348 Asp Asp Glu Ala Ser Thr Thr Val Ser Lys Thr Glu Thr Ser Gln Val Ala Pro Ala
330 331  332 333  334 335  336  337 338 339  340 341  342 343  344 345 346  347 348
Fig. 1. The amino acid sequences and numbering of CB1419–438 and Rh330–348. The phosphorylated residues are shown in italics and underlined.
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primers spanning the start and stop codons of the deduced cDNA. The
resultant PCR products were size fractionated by agarose gel electro-
phoresis. A band of 1257 bp encoding ARRB1 (arrestin-2) was puriﬁed
by silica-gel membrane adsorption (Qiagen, Chatsworth, CA) and
cloned into pCR-Blunt II-TOPO (Invitrogen, Carlsbad, CA) following
the procedures outlined in the respective manufacturer user manuals.
All constructs were veriﬁed for integrity by sequencing (University of
Connecticut Biotechnology Center, Storrs, CT). Arrestin-2 was cloned
into a commercially available recombinant protein expression system
(Invitrogen) utilizing the pTrcHisA vector from Invitrogen for high le-
vel expression in Escherichia coli. This vector (pTrcHis.Arr-2) incorpo-
rates a hexa-histidine tag allowing for the puriﬁcation of expressed
protein by immobilized metal ion aﬃnity chromatography (IMAC).
pTrcHis.Arr-2 was transformed into E. coli strain (DE3) pLysS. To
over express 6 · his-Arrestin-2 in E. coli, 1 L of LB medium was inoc-
ulated with 10 ml of overnight cell culture and induced at 30 C with
300 lM isopropyl-1-thio-b-D-galactopyranoside at a cell density of
0.6. After a 12-h incubation, cells were harvested by centrifugation
at 7500 rpm and resuspended in binding buﬀer (50 mM phosphate,
pH 8.0, 300 mM NaCl, 10% (v/v) glycerol, 2 mM 2-mercapto-ethanol,
1 mg/ml lysozyme, 0.1 mg/ml DNAse, 1 mM PMSF). The resuspended
cells were lysed using a French pressure cell and the lysate was centri-
fuged at 12000 rpm for 30 min. The supernatant was loaded onto 5 ml
Talon Resin (Clonetech) washed with 20 vol. of lysis buﬀer under grav-
ity, washed with a salt buﬀer (50 mM phosphate, pH 8.0, 300 mM
NaCl, 20 mM imidazole) and 6 · his-Arrestin-2 eluted with an imidaz-
ole containing buﬀer (50 mM phosphate, pH 8.0, 300 mM NaCl,
150 mM imidazole). A second ion-exchange puriﬁcation step was per-
formed by loading the elutions onto a 7.5 mm · 7.5 cm Alltech Pro-
sphere P-Wax column with a 50 mM Tris Buﬀer, pH 8.0 and eluted
with a 30 min linear gradient to 100% of a buﬀer comtaining
500 mM NaCl, 50 mM Tris, pH 8.0. The HPLC fractions containing
arrestin-2 were concentrated using a Centricon MWCO = 10000 (Mlli-
pore).
2.3. NMR experiments and structure calculations
The puriﬁed, concentrated arrestin-2 sample was dialyzed against a
buﬀer containing 80 mM phosphate, pH 7.2, 0.02% NaN3 at 4 C. For
preparation of the complex sample, 0.95 mg of peptide was dissolved in
70 ll dialysis buﬀer and 30 ll D20 for a ﬁnal volume of 100 ll. This
solution was added to 210 ll of the dialyzed arrestin-2 sample. The ﬁ-
nal sample volume of, 350 ll containing 0.1 mM arrestin-2, 1.14 mM
peptide at pH 7.2 (ﬁnal protein:peptide ratio of 1:10) was placed in a
shigemi tube.
Two-dimensional high-resolution proton spectra were acquired on a
Varian Unity 600 MHz spectrometer ﬁtted with a cryoprobe. DQF-
COSY, TOCSY (mix = 60 and 90 ms) and NOESY (mix = 100, 200,
400 and 600 ms) spectra of the free-peptide, free-arrestin and arres-
tin-2–peptide complexes were recorded with 2k real points, 512 incre-
ments and relaxation delay of 1 s at two diﬀerent temperatures of 10
and 20 C. Water suppression was achieved with the WATERGATE
sequence. Spectra were processed using NMRPipe.
The NMR assignment program Sparky was used for assignment and
peak integration. Distance restraints used in the structure calculations
were derived from TRNOESY experiments performed with mixing
times of 100 ms at 10 C as the NOE intensities proved to be in the lin-
ear range of the NOE buildup curve. Peaks were classiﬁed as Strong
Medium or Weak based on TRNOE cross peak volumes. Distance re-
straints of 1.8–2.7 A˚ (1.8–2.9 A˚ for NOEs involving NH protons), 1.8–
3.5 A˚ (1.8–3.7 A˚ for NOEs involving NH protons), 1.8–5.0 or 6.0 A˚
were assigned to strong, medium and weak peaks, respectively
[33,34]. The upper limits for distances involving methyl protons were
increased by an additional 0.5 A˚ [35,36].Distance restraints were used in a two-stage simulated annealing
protocol as implemented in XPLOR-NIH where randomized struc-
tures were initially ‘heated’ to 2000 K and then slowly cooled to
100 K over 3000 steps. The target function minimized during simulated
annealing was comprised of quadratic harmonic potential terms for
covalent geometry, square-well quadratic potentials for the experimen-
tal distance, and a quadratic van der Waals repulsion term for the non-
bonded contacts. Only the measured distances were employed as re-
straints in these calculations. No torsion angle restraint, hydrogen-
bonding, electrostatic, or 6–12 Lennard–Jones empirical potential en-
ergy terms were included in the target function. In the second stage,
resulting structures that successfully satisﬁed the restraints were each
used as starting structures in a second round of simulated annealing
as described above.3. Results
Proton chemical shifts and resonance assignments were estab-
lished using standard techniques [37] with TOCSY, DQF-
COSY and NOESY experiments and are reported in Table 1.
The Gly428-spin system could be identiﬁed without any diﬃ-
culty in the DQF-COSY spectrum from the characteristic alpha
protons appearing at 3.640 and 3.706 ppm and was used as a
starting point for sequential assignments. The phosphorylated
residues, Ser426 and Ser430 could be identiﬁed through the
downﬁeld chemical shifts of the amide protons and the unique
b proton chemical shifts while their sequential order was identi-
ﬁed in the NOESY ﬁngerprint region (Fig. 2). Similarly, Leu423
and Leu433 spin systems could be identiﬁed based on character-
istic COSY cross peaks between c protons (1.248 and
1.102 ppm) and the two methyl groups (0.490–0.609 ppm).
Cross peaks between c and a protons as well as amide protons
could also be observed in the TOCSY spectrum and their
sequential order identiﬁed in the NOESY ﬁngerprint region.
The Pro422 spin system was identiﬁed based on cross peaks be-
tween d (3.482, 3.345 ppm) and c protons (1.897 ppm) through
to both a and b protons observed in both COSY and TOCSY
spectra and the notable absence of couplings from these reso-
nances to the amide region. Asn425 and Asn438 was identiﬁed
based on the coupling between the two side chain amines with
the b-protons at approximately 2.4 ppm (Table 1) observed in
TOCSY and NOESY spectra. Met427 and Gln421 were identi-
ﬁed by their characteristic c protons, which appear downﬁeld as
compared to b-protons. The N-terminal amide of Thr419 is not
observed due to fast exchange with the solvent but the side
chains could be assigned based on appearance of strong b and
c proton crosspeaks. His434 and His436 were identiﬁed using
the b protons present at 2.75 ppm and cross peaks between b
protons and aromatic protons (6.8 and 7.9 ppm) in the
NOESY spectrum. The remaining residues were easily assigned
in a similar manner and could clearly be identiﬁed through cor-
relations of their sidechains.
With the addition of arrestin-2 to CB1419–438, broadening
and small changes in chemical shift were observed for several
Table 1
The 1H chemical shifts of the free and bound peptide CB1419–438
Amino acid HN a b c d  Methyl
THR419
Free 3.755 3.368 0.969
Bound 3.77 3.409 0.980
ALA420
Free 7.991 4.048 1.066
Bound 7.991 4.048 1.066
GLN421
Free 8.271 4.299 1.782, 1.620 2.090 7.339, 6.651
Bound 8.281 4.299 1.782, 1.620 2.090 7.339, 6.651
PRO422
Free 4.078 1.978, 1.596 1.722 3.475, 3.335
Bound 4.078 1.986, 1.601 1.729 3.482, 3.345
LEU423
Free 8.177 4.007 1.333 1.248 0.610, 0.562
Bound 8.184 4.003 1.333 1.248 0.609, 0.560
ASP424
Free 8.056 4.288 2.382, 2.274
Bound 8.056 4.288 2.382, 2.274
ASN425
Free 8.051 4.44 2.515, 2.443 7.419, 6.637
Bound 8.055 4.446 2.519, 2.451 7.419, 6.638
SER426
Free 8.784 4.164 3.744, 3.744
Bound 8.757 4.090 3.744, 3.744
MET427
Free 8.253 4.192 1.806, 1.736 2.215
Bound 8.253 4.195 1.810, 1.738 2.22
GLY428
Free 8.104 3.706, 3.640
Bound 8.104 3.706, 3.640
ASP429
Free 8.014 4.360 2.418, 2.354
Bound 8.005 4.359 2.418, 2.354
SER430
Free 8.764 4.095 3.744
Bound 8.757 4.090 3.744
ASP431
Free 8.258 4.278 2.383, 2.383
Bound 8.254 4.274 2.388, 2.388
CYS432
Free 7.933 4.07 2.641, 2.641
Bound 7.944 4.054 2.641, 2.641
LEU433
Free 7.993 3.899 1.213, 1.288 1.11 0.583, 0.494
Bound 7.989 3.899 1.220, 1.3 1.102 0.584, 0.490
HIS434
Free 7.919 4.325 2.866, 2.793 6.795, 7.88
Bound 7.919 4.325 2.866, 2.793 6.802, 7.887
LYS435
Free 7.852 3.898 1.402, 1.359 0.972 2.645, 7.851
Bound 7.889 3.898 1.402, 1.359 1.011 2.646, 7.872
(continued on next page)
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Table 1 (continued)
Amino acid HN a b c d  Methyl
HIS436
Free 8.189 4.339 2.877, 2.788 6.769, 7.991
Bound 8.207 4.357 2.903, 2.788 6.832, 7.991
ALA437
Free 8.1 4.27 1.050
Bound 8.1 4.27 1.057
ASN438
Free 7.862 4.152 2.442, 2.342
Bound 7.869 4.152 2.444, 2.342
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the phosphorylated residues Ser426NH and Ser430NH
(Table 1). This is indicative of a fast exchange between the free
and bound peptide state. Fig. 3 shows expanded regions
encompassing the ﬁngerprint and side chain regions from the
NOESY spectra of free Pep1A and the Pep1A-arrestin2 mix-
tures. The spectra are normalized to aide the comparison. In
the NOESY spectrum of free CB1419–438 at 20 C there are sev-
eral weak NOEs and a signiﬁcant level of noise in the peptide
spectrum. At 10 C there are a few more visible NOEs, most
likely due to a decrease in side chain motions, however, there
is no indication of secondary structure. The decreased number
of NOEs at the higher temperature and the absence of any dis-
cernible evidence of structure suggest that the peptide is highly
ﬂexible in solution. With the addition of arrestin-2 there is a
marked increase in the number and intensity of observed
NOE peaks. This observation of peaks, non-existent in freeFig. 2. Sequential assignments in the ﬁngerprint region of the NOESY spectr
acids and numbering of the peptide from 1 to 20 is used for the sake of clar
intra-residue NOEs for each residue while labels such as ‘‘5L-6D’’ indicate tpeptide, is a result of the transferred NOE phenomenon and
shows that there is a complex formed [38].
A total of 266 unambiguous NOEs were observed and uti-
lized for structure calculations. Connectivity’s observed, be-
tween NH–aH protons from residue 423 to residue 428
(Fig. 2) and NH(i)–NH(i+1) (Fig. 3) NOEs are highly suggestive
of secondary structure in the bound peptide [38]. In addition to
these there are numerous (i, i + 1) NOEs between NH–bH,
NH–cH, NH–dH, aH–bH, and aH–dH protons. There are
numerous (i, i + 1) NOEs between NH–NH, NH–aH, NH–
bH, NH–cH, NH–dH, aH–bH, and aH–dH protons. In addi-
tion there are numerous (i, i + 3) transferred NOE peaks such
as Asp424aH-Met427NH, Asn425aH-Gly428NH, Gly428aH-
Asp431NH, Asp429aH-Cys432NH, Ser430aH-Leu433NH.
Inter-residue NOEs are summarized in Fig. 4 and argue in fa-
vor of a helical structure for the segments of the peptide near
the phosphorylated serine sites.um of the CB1419–438-arrestin-2 complex. The one letter codes of amino
ity (see Fig. 1 for numbering). Labels such as ‘‘5L’’ indicate the NH–a
he ai-NHi+1 inter-residue NOEs.
Fig. 3. Panel (A) NOESY spectra of free CB1419–438 (peptide) and CB1419–438-arrestin2 mixtures (complex) at 10 C and at two diﬀerent mixing
times. Panel (B) NOESY spectra of free CB1419–438 and CB1419–438-arrestin 2 mixtures (complex) at 20 C and at two diﬀerent mixing times. Panel (C)
NH–NH region of NOESY spectra of free CB1419–438 (peptide) and CB1419–438-arrestin2 mixture (complex) at 10 C.
Fig. 4. Summary of inter-residue NOEs and structural statistics of the
ordered regions of the peptide (423–433) generated using PRO-
CHECK. Approximately 90% of these residues occur in favored and
allowed regions of the Ramachandran plot with less than 5% occurring
in disallowed regions. The residues that fall in the allowed or
generously allowed regions were the residues that borderer the ordered
helices and fell within the ﬂexible region near the glycine.
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Despite the fact that resonances could all be identiﬁed from
side chain cross peaks, spectral overlap resulted in diﬃculty in
unambiguously assigning certain NOE’s. For example, in the
case of expected aN(i, i + 1) cross peaks in the ﬁngerprint re-
gion, overlap of amide proton chemical shifts of Asp424 and
Asn425 result in an ambiguous assignment of the 424Ha–
425HN cross peak hence these were omitted from structure
calculations. Similarly, overlap of amide chemical shifts of
Met427NH and Asp431NH makes it cumbersome to diﬀeren-
tiate between an assignment of Met427NH–Asp427NH and
Asp429NH–Asp431NH for this crosspeak. Similarly the high
degree of overlap between Ser426 and Ser430 amides made
assignments of certain potential long range NOEs ambiguous.
For example the NOE from Asn425NH-Ser426NH may also
be interpreted as Asn425NH-Ser430NH. In these cases the
more conservative short-range assignment was used as a re-
straint in the initial structure calculations.
The conformation of CB1419–438 when bound to arrestin-2
was calculated using the NOEs as distance restraints in a sim-
ulated annealing protocol in XPLOR. A set of one hundred
structures produced by simulated annealing were reﬁned using
no contribution from the van der waals term, followed by
checks for agreement with the assigned distance restraints.
No violations of distance restraints greater than 0.3–0.5 A
were allowed. Of the allowed structures, there was a family
of 33 structures that clearly possessed the lowest energies.
When aligned across the entire length of the peptide these
structures showed a reasonable RMSD value between them
Fig. 6. Comparison of: (A) a minimum energy conformer of
diphosphorylated CB1419–438 fragment bound to arrestin and (B) the
seven phosphorylated Rh330–348 fragment bound to visual arrestin.
This later structure was downloaded from the protein data bank
(www.rcsb.org.1NZS.pdb) and oriented to highlight the similarity of
the C-terminal end with CB1419–438. The phosphorylated residues are
highlighted by CPK representations.
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ensemble of thirty-three structures, showed two highly ordered
segments (Fig. 5). Alignment of the backbone atoms between
the residues Pro423-Met427 gave an RMSD of 0.72 ± 0.2
and a second alignment of backbone atoms between residues
Asp429-Leu433 gave an RMSD of 0.44 ± 0.08 (Fig. 4).
The results show that the diphosphorylated peptide CB1419–
438 undergoes structural changes upon binding to arrestin-2.
The lowest energy structure that ﬁts the experimental restraints
shows that the N terminal region up to Pro422 is disordered
and the rest of the peptide encompasses two helical segments
from Leu423-Gly428 and from Asp429-Leu433 (Fig. 5). This
is consistent with the role of proline to form an end cap to-
wards the N-terminal side of helices and of glycine to interrupt
alpha-helix structures due to its high degree of ﬂexibility and
lack of hydrophobic stabilization [39]. The higher RMSD val-
ues calculated over the entire length of the peptide is due to the
fact that the GLY428 residue acts as a hinge point so that the
angle between the two ordered segments can vary as is illus-
trated in Fig. 5.
A previous study by Kisselev et al. has determined the con-
formation of a peptide (Rh330–348) (Fig. 1) mimicking the last
nineteen residues of the rhodopsin (Rh) receptor with visual
arrestin (or arrestin-1). The similarity of the observed arrestin
structures across the family combined with the fact that muta-
genic sensitive residues are largely conserved across all arres-
tins [23] has prompted conclusions from diﬀerent studies to
be applied across the family to in order to gain insights into
the in situ mechanism of action. This warrants a comparison
of the structures of bound CB1419–438 to arrestin-2 and bound
Rh330–348 to arrestin-1. The C-termini of the two GPCRs have
no sequence homology. The peptide Rh330–348 mimics a seg-
ment of the rhodopsin C-terminus that is immediately adjacent
to helix eight, a portion of the C-terminus close to the cell
membrane known to form a helix that associates with the
membrane surface [40]. The C-terminus of CB1 is approxi-
mately 25 residues longer than that of rhodopsin however
CB1419–438 is estimated to also be adjacent to helix eight of
CB1 [31].Fig. 5. NMR derived structures of CB1419–438 fragment bound to arrestin-2. (
same set of structures are aligned from residue 429–433 (C) The ordered reg
between the two ordered regions.We observe binding of CB1419–438 with a diphosphorylated
peptide, whereas Rh330–348 contained seven phosphorylated
sites (Fig. 1). Binding with this low level of phosphorylation is
consistent with data indicating that only one or two phosphor-
ylation sites are necessary for an observable interactionwith arr-
estin [41,42]. Furthermore, the structural changes observed in
this study bear similarities to the structural changes reported
for Rh330–348 upon binding (Fig. 6) [27,28]. In each case, a-heli-
ces are induced towards the C-terminal end of each peptide
(Fig. 6). In the case of Rh330–348, it was predicted that this struc-
tural element would also be observable with a single phosphor-
ylation at Ser343 [27]. The current results for CB1419–438 support
this prediction. The CB1-Ser430 is analogous to the Rh-Ser343
phosphorylation site in that it is located in approximately the
same relative position in the induced helix of the peptideA) The low energy structures are aligned from residue 422–427. (B) The
ions are shown together to emphasize the ﬂexible GLY428 present in
K. Bakshi et al. / FEBS Letters 581 (2007) 5009–5016 5015(Fig. 6). This structural similarity between two peptides with no
sequence homology that are interacting with two diﬀerent mem-
bers of the arrestin family, further argues in favor of the notion
that this is a structure imposed by arrestins that is functionally
signiﬁcant rather than a potential artifact caused by an indiscri-
minant association of the highly phosphorylated Rh330–348 with
the many arrestin surface charges.
On the N-terminal side of CB1419–438 there is another short
helix, separated from the C-terminal helix by GLY428 (Figs. 5
and 6). This is in contrast to Rh330–348 which shows a loop that
brings the N and C-termini of the peptide close to each other
(Fig. 6). It is possible that these diﬀerences are due to the dif-
ferences between arrestin-1 and arrestin-2 and/or the sequences
of the two peptides. Another interpretation, however, is that
the decreased level of phosphorylation in this portion of
CB1419–438 compared to Rh330–348 allows the formation of this
second helix [43]. The increased phosphorylation in this vicin-
ity of Rh330–348 may prevent a helix from forming in this case,
due to the increased association with charges on the surface of
the protein.
Previously published data suggests that phosphorylation at
both Ser426 and Ser430 is necessary for desensitization of
the CB1 receptor [20]. This is consistent with the fact that
the arrestin bound CB1419–438 shows structured regions in
the vicinity of both the phosphorylated serines. This data ta-
ken together suggests that both phosphates are accommodated
within the arrestin binding site. Comparison of the conforma-
tions of CB1419–438 with Rh330–348 also shows that the induced
helices are relatively short, extending over no more than ﬁve
amino acid residues. This might be suggestive of the size of
binding pocket on the arrestin molecule. The ﬂexibility of
CB1419–438 between the two helical regions is a particularly
striking feature. The fact that two helices are observed in the
case of CB1419–438 may point to a functional signiﬁcance of
the ﬂexible hinge point about Gly428. This may aﬀect the aﬃn-
ity of the phosphorylated peptide for the binding site in that it
may allow these helices to be better accommodated within the
binding site.
In summary, CB1419–438 undergoes a conformational change
upon binding to arrestin where helices are induced in the vicin-
ity of the two-phosphorylation sites. The consistencies with the
bound structure of Rh330–348 suggest that the arrestin imposes
this structure and this imposed structure may be aﬀected by the
degree of phosphorylation. Taken together with literature evi-
dence showing that the phosphorylation pattern may aﬀect the
functional outcome of the GPCR-arrestin interaction [19–21],
our results prompt the speculation that the structural details of
the high aﬃnity complex between the C-terminus of GPCRs
and arrestin-2 may vary depending on the nature of the phos-
phorylation, however this remains to be tested.
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